Alto Neuroscience's ALTO-300, a novel biomarker-based antidepressant, advances in Phase 2b trial for Major Depressive Disorder with topline results expected by mid-2026.
ImmuneOnco has dosed the first patient in a Phase 1b/2 trial of IMM2510/SYN-2510 with chemotherapy for advanced non-small cell lung cancer (NSCLC) in China.
Jefferies has upgraded Instil Bio, citing the promising potential of its investigational cancer drug SYN2510. The upgrade follows significant clinical trial updates and a bullish outlook on the PD-(L)1xVEGF class, with Jefferies estimating a market potential of over $40 billion. Instil Bio's stock saw a substantial increase, reflecting the industry's optimism towards SYN2510's clinical and commercial prospects.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.